Patents Examined by Aradhana Sasan
  • Patent number: 11325955
    Abstract: Methods of generating and optimizing stabilized (e.g., stapled and/or stitched) anti-microbial peptides (StAMPs) for the prophylaxis and treatment of antibiotic-resistant (e.g., colistin-resistant, methicillin resistant, meropenem-resistant) bacterial infections (e.g., Gram-negative, Gram-positive), and methods for using such peptides for experimental investigation, livestock management, management of crops/trees/plants, and/or therapeutic benefit. Also featured are methods for reducing renal toxicity of a StAMP.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: May 10, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Rida Mourtada
  • Patent number: 11318190
    Abstract: Disclosed is a method of modulating the Sct/SR axis in a mammalian subject in need thereof, including in a subject suffering from a liver disease, such as but not limited to, Early Stage PBC, Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, Biliary Altresia, NASH, NAFLD, or Alcohol induced liver injury. A method of treating Late Stage PBC in a mammalian subject in need thereof is also disclosed; further disclosed is a method of ameliorating PBC-induced biliary damage in a mammalian subject in need thereof. Pharmaceutical compositions for modulating the Sct/SR axis, comprising a SR antagonist or a SR agonist, and a pharmaceutically acceptable carrier or excipient are also disclosed.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: May 3, 2022
    Assignee: UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Gianfranco Alpini, Shannon Glaser, Fanyin Meng
  • Patent number: 11311606
    Abstract: Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin ?-4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: April 26, 2022
    Assignee: GEORGETOWN UNIVERSITY
    Inventors: Christopher Albanese, Aisha Naeem
  • Patent number: 11304972
    Abstract: A topical application of nitric oxide may be provided by two separate containers, each containing an active component media to produce nitric oxide when combined. For example, a nitrite component media may be contained in one dispenser and an acidified component media may be contained in another dispenser. Each dispenser may dispense the respective component media as a foam. The resultant foams are combined to initiate the production of nitric oxide and the mixture of foams is applied topically to treat various skin disorders or wounds.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: April 19, 2022
    Assignee: Syk Technologies LLC
    Inventors: C. Michael Miller, Gordon K. Hill, A. John Pate, David A. Bell
  • Patent number: 11306121
    Abstract: The present invention relates to a peptide exhibiting physiological activities and a composition including the peptide. Because the peptide of the present invention exhibits various physiological activities such as muscle relaxation, skin wrinkle improvement, sebum production suppression, and the like, the peptide may be used as an active ingredient in a pharmaceutical composition for muscle relaxation, or cosmetics for improving skin wrinkles, suppressing sebum production, or ameliorating acne.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: April 19, 2022
    Assignee: Caregen Co., Ltd.
    Inventors: Yong Ji Chung, Eun Mi Kim, Eung Ji Lee
  • Patent number: 11298400
    Abstract: Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year. The methods are capable of providing an enhanced therapeutic effect in treating nocturia, and in improving urinary flow, when compared to the therapeutic effect achieved by administration of the same or twice the total amount of FT administered.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: April 12, 2022
    Assignee: NYMOX CORPORATION
    Inventor: Paul Averback
  • Patent number: 11298323
    Abstract: This invention relates to a bioerodible drug delivery device that can be implanted in a patient at or near an area in need of treatment. The bioerodible drug delivery device can be used to deliver a wide variety of different pharmaceutically active agents, and can do so at a controlled rate and over an extended period of time. The bioerodible drug delivery device includes a bioerodible polymeric outer housing with one or more delivery ports for delivering the pharmaceutically active agent(s) contained therein. The polymer used as the bioerodible polymeric outer housing is not substantially degraded during the dosing of the pharmaceutically active agent(s) in the bioerodible drug delivery device. The invention also provides methods of making the bioerodible drug delivery device and using it for the treatment of diseases and disorders.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: April 12, 2022
    Assignee: EYEPOINT PHARMACEUTICALS, INC.
    Inventors: Hong Guo, Jianbing Chen
  • Patent number: 11298312
    Abstract: The present invention relates to a topical composition and more particularly a topical composition for antimicrobial benefit. According to the present invention there is provided a topical composition comprising Niacinamide and picolinamide wherein the molar ratio of Niacinamide to picolinamide is from I:20 to 20:I.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: April 12, 2022
    Assignee: CONOPCO, INC.
    Inventors: Amitabha Majumdar, Mruthyunjaya Swamy Mathapathi
  • Patent number: 11291648
    Abstract: The present disclosure is directed to a composition comprising micronized cromolyn sodium, ?-lactose, and a salt of fatty acid, wherein the ?-lactose has a particle size distribution of D90 of 45-70 ?m, D50 of 10-35 ?m, and D10 of 2-13 ?m. The present disclosure is also directed to a method of treating Alzheimer's disease, amyloidosis-associated condition (AAC), traumatic brain injury, Huntington's disease, atherosclerosis, cytokine release syndrome (CRS), dementia, head injury, infection, neuroinflammation, prion disease, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, or asthma using the composition.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: April 5, 2022
    Assignees: The General Hospital Corporation, AZTherapies, Inc.
    Inventors: David R. Elmaleh, Juan B. Gonzalez
  • Patent number: 11291701
    Abstract: The present invention is related to an orally disintegrating, sublingual or buccal formulation of active ingredient such as cannabidiol or tetrahydrocannabinol.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: April 5, 2022
    Assignee: SEED EDIBLES
    Inventor: Danny S. Gonzalez
  • Patent number: 11286489
    Abstract: The present invention is directed to a composition that includes an amphiphile, its use in a method of preventing and/or treating cancer, and its use in a method of producing a pharmaceutical composition. In certain embodiments, the amphiphile includes a hydrophilic peptide that binds to a Plenty of SH3 domain (POSH) and inhibits or disrupts a POSH scaffold network, a hydrophobic moiety, and an aptamer. The present invention is also directed to other POSH inhibitor complex biomolecules that do not contain a hydrophobic moiety.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: March 29, 2022
    Assignee: THE CURATORS OF THE UNIVERSITY OF MISSOURI
    Inventors: Mark Daniels, Bret Ulery, David Porciani, Kwaku Tawiah, Josiah Smith, Leah Cardwell, Donald Burke, Erin Newcomer
  • Patent number: 11278588
    Abstract: Disclosed are methods of treating symptoms of Lower Urinary Tract Symptoms (LUTS), both obstructive and irritative, that include identifying patients having benign prostatic hyperplasia (BPH), and who also have LUTS, and administering a composition comprising FT to the so-identified patient. The methods are particularly effective in improving urinary peak flow (Qmax), and in improving nocturia.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: March 22, 2022
    Assignee: NYMOX CORPORATION
    Inventor: Paul Averback
  • Patent number: 11278649
    Abstract: Described herein are substrate coatings.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: March 22, 2022
    Assignee: MicroVention, Inc.
    Inventors: Aaron Baldwin, John Belletto, Wendy Beuthin
  • Patent number: 11273128
    Abstract: A pharmaceutical formulation is disclosed which includes at least: (1) elagolix sodium, (2) magnesium oxide, and (3) at least one disintegrating agent, such as crospovidone, croscarmellose sodium, sodium starch glycolate, pregelatinized and mixtures thereof. A tablet is also disclosed which includes a tablet core formed from the pharmaceutical formulation. The elagolix sodium tablets of the present disclosure display improved dissolution rates when tested using for example the Tablet Sink Time test. The tablets also exhibit improved storage stability of the elagolix sodium, with a reduction in degradation products during storage.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: March 15, 2022
    Assignee: Sandoz AG
    Inventors: Vivek Battu, Akash Vijay Lingayat, Amit Gupta, Anandkrishna Laxmikant Kulkanri
  • Patent number: 11267853
    Abstract: The invention features a compositions and methods for inducing an immune response to targeted cells. The compositions induce targeting of a cell by positioning carbohydrate epitopes on the surface of the cell by conjugation of the epitope to a pH-triggered membrane peptide (pHLIP®).
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: March 8, 2022
    Assignees: University of Rhode Island Board of Trustees, Yale University
    Inventors: Yana K. Reshetnyak, Oleg A. Andreev, Anna Moshnikova, Donald M. Engelman
  • Patent number: 11266598
    Abstract: The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.
    Type: Grant
    Filed: April 21, 2021
    Date of Patent: March 8, 2022
    Assignee: ELLODI PHARMACEUTICALS, L.P.
    Inventors: Stephen Perrett, Fredric Jay Cohen, Gopi M. Venkatesh
  • Patent number: 11253464
    Abstract: Anhydrous compositions including from 3% to 15% by weight of at least one lipophilic gelling agent, from 10% to 50% by weight of fillers including at least 5% by weight of a first filler and at least 5% by weight of a second filler different from the first; and from 40% to 85% by weight of at least one fatty phase are provided.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: February 22, 2022
    Assignee: L'OREAL
    Inventors: Valerie Page, Sophie Guilbaud, Celine Demarcq
  • Patent number: 11246828
    Abstract: The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: February 15, 2022
    Assignee: ELLODI PHARMACEUTICALS, L.P.
    Inventors: Stephen Perrett, Fredric Jay Cohen, Gopi M. Venkatesh
  • Patent number: 11224656
    Abstract: There are provided, inter alia, compositions including a scintillator nanocrystal linked to a chemical agent moiety through a scintillator-activated photocleavable linker, and methods of use thereof.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: January 18, 2022
    Assignee: The Regents of the University of California
    Inventors: Milan T. Makale, Wolfgang J. Wrasidlo, Santosh Kesari, Joanna McKittrick, Gustavo A. Hirata Flores, Olivia Graeve
  • Patent number: 11224575
    Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: January 18, 2022
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Geert Verreck